v3.26.1
Segment Reporting - Schedule of Single Reportable Segment Profit or Loss information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Net revenue $ 4,055,000 $ 1,881,000
Less:    
Cost of revenues 1,668,000 983,000
Personnel-related expenses and board fees 12,823,000 11,000,000
Professional fees, legal, and outside services 7,974,000 5,008,000
Facilities and insurance 1,758,000 2,071,000
Laboratory supplies and expenses 3,930,000 1,826,000
Marketing and advertising 582,000 257,000
Travel and entertainment 849,000 585,000
Other segment items [1] 633,000 81,000
Segment loss from operations (26,162,000) (19,930,000)
Reconciliation of segment profit and loss:    
Depreciation and amortization expenses (2,197,000) (1,564,000)
Stock-based compensation (2,219,000) (1,753,000)
Change in fair value of contingent consideration (5,946,000) 4,275,000
Impairment losses (14,600,000) (41,900,000)
Impairment loss on held for sale assets 0 (169,000)
Interest expense (109,000) (84,000)
Other income, net 1,011,000 462,000
Income taxes 0 0
Net loss (50,222,000) (60,663,000)
Laboratory Services [Member]    
Segment Reporting Information [Line Items]    
Net revenue 4,031,000 1,859,000
Laboratory Developed Test Services [Member]    
Segment Reporting Information [Line Items]    
Net revenue 0 22,000
Kitted Products [Member]    
Segment Reporting Information [Line Items]    
Net revenue $ 24,000 $ 0
[1] Other segment items primarily includes clinical trial expenses, delivery expenses, other business taxes and tax credits, and severance costs. For the years ended December 31, 2025 and 2024, clinical trial expenses were $301,000 and $2,000, respectively.